

Maria Elena Bottazzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6428906/publications.pdf>

Version: 2024-02-01

212
papers

10,742
citations

30070

54
h-index

43889

91
g-index

228
all docs

228
docs citations

228
times ranked

12379
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. <i>Annual Review of Medicine</i> , 2022, 73, 55-64.	12.2	55
2	Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. <i>Protein Expression and Purification</i> , 2022, 190, 106003.	1.3	21
3	The silent and dangerous inequity around access to COVID-19 testing: A call to action. <i>EClinicalMedicine</i> , 2022, 43, 101230.	7.1	33
4	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	57
5	Biochemical Screening of Potent Zika Virus Protease Inhibitors. <i>ChemMedChem</i> , 2022, 17, e202100695.	3.2	7
6	Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice. <i>Frontiers in Immunology</i> , 2022, 13, 800295.	4.8	4
7	Reviewing a Decade of Outpatient Tropical Medicine in Houston, Texas. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 1049-1056.	1.4	1
8	Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study. <i>Lancet Public Health</i> , The, 2022, 7, e356-e365.	10.0	41
9	Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With <i>Onchocerca ochengi</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 869039.	3.9	5
10	Vaxi-DL: A web-based deep learning server to identify potential vaccine candidates. <i>Computers in Biology and Medicine</i> , 2022, 145, 105401.	7.0	7
11	Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. <i>Vaccine</i> , 2022, 40, 3655-3663.	3.8	21
12	Co-Administration of Adjuvanted Recombinant Ov-103 and Ov-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine <i>Onchocerca ochengi</i> Infection Model of Human Onchocerciasis. <i>Vaccines</i> , 2022, 10, 861.	4.4	5
13	Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine. <i>Expert Review of Vaccines</i> , 2022, 21, 1185-1203.	4.4	3
14	CspZ FH-Binding Sites as Epitopes Promote Antibody-Mediated Lyme <i>Borrelia</i> Clearance. <i>Infection and Immunity</i> , 2022, 90, .	2.2	3
15	Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights. <i>Expert Review of Vaccines</i> , 2022, 21, 1405-1417.	4.4	1
16	Mining the Metabolome for New and Innovative Chagas Disease Treatments. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 1-3.	8.7	3
17	Vaccination with chimeric protein induces protection in murine model against ascariasis. <i>Vaccine</i> , 2021, 39, 394-401.	3.8	14
18	Preparing for SARS-CoV-2 Vaccines in US Immigrant Communities: Strategies for Allocation, Distribution, and Communication. <i>American Journal of Public Health</i> , 2021, 111, 577-581.	2.7	9

#	ARTICLE	IF	CITATIONS
19	A scalable and reproducible manufacturing process for <i>Phlebotomus papatasi</i> salivary protein PpSP15, a vaccine candidate for leishmaniasis. <i>Protein Expression and Purification</i> , 2021, 177, 105750.	1.3	4
20	Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 275-285.	9.1	27
21	Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute <i>Trypanosoma cruzi</i> infection. <i>Scientific Reports</i> , 2021, 11, 3222.	3.3	20
22	Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. <i>Lancet</i> , The, 2021, 397, 562-564.	13.7	105
23	Correcting COVID-19 vaccine misinformation. <i>EClinicalMedicine</i> , 2021, 33, 100780.	7.1	63
24	Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission. <i>Lancet</i> , The, 2021, 397, 947-950.	13.7	26
25	Repeat-Driven Generation of Antigenic Diversity in a Major Human Pathogen, <i>Trypanosoma cruzi</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 614665.	3.9	25
26	Advances in vaccine development for human trichuriasis. <i>Parasitology</i> , 2021, , 1-12.	1.5	6
27	Alterations to the Cardiac Metabolome Induced by Chronic <i>T. cruzi</i> Infection Relate to the Degree of Cardiac Pathology. <i>ACS Infectious Diseases</i> , 2021, 7, 1638-1649.	3.8	17
28	SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2356-2366.	3.3	64
29	The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine. <i>American Journal of Preventive Medicine</i> , 2021, 60, 605-613.	3.0	28
30	Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination. <i>Journal of Infectious Diseases</i> , 2021, 224, 938-948.	4.0	32
31	Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 4153-4165.	3.6	37
32	Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment. <i>EClinicalMedicine</i> , 2021, 36, 100925.	7.1	11
33	Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129893.	2.4	49
34	Urgent needs to accelerate the race for COVID-19 therapeutics. <i>EClinicalMedicine</i> , 2021, 36, 100911.	7.1	7
35	A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. <i>Science Immunology</i> , 2021, 6, .	11.9	53
36	Operation Warp Speed: implications for global vaccine security. <i>The Lancet Global Health</i> , 2021, 9, e1017-e1021.	6.3	72

#	ARTICLE	IF	CITATIONS
37	Signal Transducer and Activator of Transcription-3 Modulation of Cardiac Pathology in Chronic Chagasic Cardiomyopathy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 708325.	3.9	9
38	Immunomics-guided discovery of serum and urine antibodies for diagnosing urogenital schistosomiasis: a biomarker identification study. <i>Lancet Microbe, The</i> , 2021, 2, e617-e626.	7.3	14
39	Potency testing for a recombinant protein vaccine early in clinical development: Lessons from the <i>Schistosoma mansoni</i> Tetraspanin 2 vaccine. <i>Vaccine: X</i> , 2021, 8, 100100.	2.1	3
40	Location and expression kinetics of Tc24 in different life stages of <i>Trypanosoma cruzi</i> . <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009689.	3.0	9
41	Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed. <i>PLoS Medicine</i> , 2021, 18, e1003772.	8.4	7
42	Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. <i>EClinicalMedicine</i> , 2021, 39, 101053.	7.1	45
43	Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. <i>Scientific Reports</i> , 2021, 11, 17626.	3.3	42
44	Characterization of T cell responses to co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in healthy adults in Gabon. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009732.	3.0	6
45	<i>Onchocerca volvulus</i> bivalent subunit vaccine induces protective immunity in genetically diverse collaborative cross recombinant inbred intercross mice. <i>Npj Vaccines</i> , 2021, 6, 17.	6.0	11
46	Diversity, Equity, and Inclusion in the Microbial Sciences—the Texas Perspective. <i>MBio</i> , 2021, 12, e0262021.	4.1	1
47	Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant. <i>Microorganisms</i> , 2021, 9, 2253.	3.6	10
48	Controlled Infection of Humans with the Hookworm Parasite <i>Necator americanus</i> to Accelerate Vaccine Development. <i>Current Topics in Microbiology and Immunology</i> , 2021, , 1.	1.1	4
49	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. <i>Science Translational Medicine</i> , 2021, , eabj5305.	12.4	4
50	Transient <i>Ascaris suum</i> larval migration induces intractable chronic pulmonary disease and anemia in mice. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0010050.	3.0	10
51	ASCVac-1, a Multi-Peptide Chimeric Vaccine, Protects Mice Against <i>Ascaris suum</i> Infection. <i>Frontiers in Immunology</i> , 2021, 12, 788185.	4.8	5
52	Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. <i>Vaccine</i> , 2020, 38, 7533-7541.	3.8	84
53	Host Immunity and Inflammation to Pulmonary Helminth Infections. <i>Frontiers in Immunology</i> , 2020, 11, 594520.	4.8	26
54	Coronavirus vaccine-associated lung immunopathology-what is the significance?. <i>Microbes and Infection</i> , 2020, 22, 403-404.	1.9	15

#	ARTICLE	IF	CITATIONS
55	Disproportionate impact of the COVID-19 pandemic on immigrant communities in the United States. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008484.	3.0	256
56	Developing a low-cost and accessible COVID-19 vaccine for global health. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008548.	3.0	66
57	<i>Schistosoma haematobium</i> Extracellular Vesicle Proteins Confer Protection in a Heterologous Model of Schistosomiasis. <i>Vaccines</i> , 2020, 8, 416.	4.4	27
58	Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. <i>American Journal of Preventive Medicine</i> , 2020, 59, 493-503.	3.0	259
59	Lancet COVID-19 Commission Statement on the occasion of the 75th session of the UN General Assembly. <i>Lancet, The</i> , 2020, 396, 1102-1124.	13.7	117
60	Global COVID-19 Efforts as the Platform to Achieving the Sustainable Development Goals. <i>Current Tropical Medicine Reports</i> , 2020, 7, 99-103.	3.7	25
61	The Factor H-Binding Site of CspZ as a Protective Target against Multistrain, Tick-Transmitted Lyme Disease. <i>Infection and Immunity</i> , 2020, 88, .	2.2	13
62	Safety and immunogenicity of a recombinant vaccine against <i>Trypanosoma cruzi</i> in Rhesus macaques. <i>Vaccine</i> , 2020, 38, 4584-4591.	3.8	16
63	Central Latin America: Two decades of challenges in neglected tropical disease control. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0007962.	3.0	22
64	COVID-19 vaccines: neutralizing antibodies and the alum advantage. <i>Nature Reviews Immunology</i> , 2020, 20, 399-400.	22.7	74
65	The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission. <i>Vaccine</i> , 2020, 38, 3261-3270.	3.8	7
66	TLR4 agonist protects against <i>Trypanosoma cruzi</i> acute lethal infection by decreasing cardiac parasite burdens. <i>Parasite Immunology</i> , 2020, 42, e12769.	1.5	14
67	Process Characterization and Biophysical Analysis for a Yeast-Expressed <i>Phlebotomus papatasi</i> Salivary Protein (PpSP15) as a <i>Leishmania</i> Vaccine Candidate. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 1673-1680.	3.3	8
68	The SARS-CoV-2 Vaccine Pipeline: an Overview. <i>Current Tropical Medicine Reports</i> , 2020, 7, 61-64.	3.7	403
69	Protective immunity elicited by the nematode-conserved As37 recombinant protein against <i>Ascaris suum</i> infection. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008057.	3.0	25
70	The Potential Economic Value of a Zika Vaccine for a Woman of Childbearing Age. <i>American Journal of Preventive Medicine</i> , 2020, 58, 370-377.	3.0	1
71	COVID-19 vaccine design: the Janus face of immune enhancement. <i>Nature Reviews Immunology</i> , 2020, 20, 347-348.	22.7	155
72	The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement. <i>Microbes and Infection</i> , 2020, 22, 165-167.	1.9	103

#	ARTICLE	IF	CITATIONS
73	Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 1239-1242.	3.3	120
74	Will COVID-19 become the next neglected tropical disease?. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008271.	3.0	22
75	A new patient registry for Chagas disease. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008418.	3.0	8
76	COVID-19 in the Americas and the erosion of human rights for the poor. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008954.	3.0	10
77	Use of Multi-Parallel Real-Time Quantitative PCR to Determine Blastocystis Prevalence and Association with Other Gastrointestinal Parasite Infection in a Rural Honduran Location. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 102, 1373-1375.	1.4	9
78	Reproductive Outcomes in Rhesus Macaques (<i>Macaca mulatta</i>) with Naturally-acquired <i>Trypanosoma cruzi</i> Infection. <i>Comparative Medicine</i> , 2020, 70, 152-159.	1.0	4
79	I Never Thought I Had "Moral Courage," until COVID-19 Happened. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 551-551.	1.4	0
80	Neglected Parasitic Infections and the Syndemic Anemia Vaccines for Africa. , 2019, , 75-85.		2
81	Response to "letter to the editor: "Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America". <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 673-675.	4.4	3
82	Improved Biomarker and Imaging Analysis for Characterizing Progressive Cardiac Fibrosis in a Mouse Model of Chronic Chagasic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2019, 8, e013365.	3.7	21
83	Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to <i>Onchocerca volvulus</i> infection in both mice and humans. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007730.	3.0	18
84	Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens. <i>Vaccines</i> , 2019, 7, 131.	4.4	29
85	A method to probe protein structure from UV absorbance spectra. <i>Analytical Biochemistry</i> , 2019, 587, 113450.	2.4	37
86	China's shifting neglected parasitic infections in an era of economic reform, urbanization, disease control, and the Belt and Road Initiative. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0006946.	3.0	11
87	A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic <i>Trypanosoma cruzi</i> infection. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007413.	3.0	40
88	"Running the Gauntlet": Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a "Call to Action". <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2235-2242.	3.3	22
89	Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. <i>Vaccine</i> , 2019, 37, 3704-3714.	3.8	12
90	Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 145-157.	4.4	77

#	ARTICLE	IF	CITATIONS
91	Inspiring women scientists in Honduras. <i>EBioMedicine</i> , 2019, 49, 21.	6.1	1
92	Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of <i>Trypanosoma cruzi</i> infection in mice. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 210-219.	3.3	33
93	Advancing the Development of a Human Schistosomiasis Vaccine. <i>Trends in Parasitology</i> , 2019, 35, 104-108.	3.3	41
94	Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. <i>Vaccine</i> , 2018, 36, 1853-1862.	3.8	62
95	Characterization and Stability of <i>Trypanosoma cruzi</i> Tc24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1468-1473.	3.3	23
96	Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease. <i>Infection and Immunity</i> , 2018, 86, .	2.2	47
97	<i>Onchocerca volvulus</i> : The Road from Basic Biology to a Vaccine. <i>Trends in Parasitology</i> , 2018, 34, 64-79.	3.3	36
98	IgG Induced by Vaccination With <i>Ascaris suum</i> Extracts Is Protective Against Infection. <i>Frontiers in Immunology</i> , 2018, 9, 2535.	4.8	36
99	<i>Ascaris</i> Larval Infection and Lung Invasion Directly Induce Severe Allergic Airway Disease in Mice. <i>Infection and Immunity</i> , 2018, 86, .	2.2	30
100	Ligand binding properties of two <i>Brugia malayi</i> fatty acid and retinol (FAR) binding proteins and their vaccine efficacies against challenge infection in gerbils. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006772.	3.0	16
101	<i>Trichuris muris</i> whey acidic protein induces type 2 protective immunity against whipworm. <i>PLoS Pathogens</i> , 2018, 14, e1007273.	4.7	18
102	Controlled Human Hookworm Infection: Accelerating Human Hookworm Vaccine Development. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy083.	0.9	37
103	The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4 + T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway. <i>Vaccine</i> , 2018, 36, 3650-3665.	3.8	7
104	Lessons along the Critical Path: Developing Vaccines against Human Helminths. <i>Trends in Parasitology</i> , 2018, 34, 747-758.	3.3	41
105	Covalent vaccination with <i>Trypanosoma cruzi</i> Tc24 induces catalytic antibody production. <i>Parasite Immunology</i> , 2018, 40, e12585.	1.5	4
106	A novel blood-feeding detoxification pathway in <i>Nippostrongylus brasiliensis</i> L3 reveals a potential checkpoint for arresting hookworm development. <i>PLoS Pathogens</i> , 2018, 14, e1006931.	4.7	24
107	<i>Trypanosoma cruzi</i> vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006240.	3.0	31
108	Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 1961-1970.	3.3	95

#	ARTICLE	IF	CITATIONS
109	A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations. <i>Vaccine</i> , 2017, 35, 1410-1416.	3.8	1
110	Mutations to Cysteine Residues in the <i>Trypanosoma cruzi</i> B-Cell Superantigen Tc24 Diminish Susceptibility to IgM-Mediated Hydrolysis. <i>Journal of Parasitology</i> , 2017, 103, 579-583.	0.7	3
111	Genetic Adjuvantation of a Cell-Based Therapeutic Vaccine for Amelioration of Chagasic Cardiomyopathy. <i>Infection and Immunity</i> , 2017, 85, .	2.2	16
112	Human Hookworm Disease: Alternative Strategies to Achieve the Global Health Agenda for Elimination. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 223-229.	1.9	0
113	Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 621-633.	3.3	39
114	Expression, purification, immunogenicity and protective efficacy of a recombinant nucleoside hydrolase from <i>Leishmania donovani</i> , a vaccine candidate for preventing cutaneous leishmaniasis. <i>Protein Expression and Purification</i> , 2017, 130, 129-136.	1.3	11
115	Identification, Characterization, and Structure of Tm16 from <i>Trichuris muris</i> . <i>Journal of Parasitology Research</i> , 2017, 2017, 1-10.	1.2	10
116	Structure of SALO, a leishmaniasis vaccine candidate from the sand fly <i>Lutzomyia longipalpis</i> . <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005374.	3.0	11
117	Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005574.	3.0	60
118	Yeast-expressed recombinant As16 protects mice against <i>Ascaris suum</i> infection through induction of a Th2-skewed immune response. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005769.	3.0	30
119	2257. <i>Journal of Clinical and Translational Science</i> , 2017, 1, 60-60.	0.6	0
120	Advances in neglected tropical disease vaccines: Developing relative potency and functional assays for the Na-GST-1/Alhydrogel hookworm vaccine. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005385.	3.0	12
121	Human Intestinal Parasite Burden and Poor Sanitation in Rural Alabama. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1623-1628.	1.4	107
122	The BENEFIT Trial: Where Do We Go from Here?. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004343.	3.0	112
123	Vaccination of Gerbils with Bm-103 and Bm-RAL-2 Concurrently or as a Fusion Protein Confers Consistent and Improved Protection against <i>Brugia malayi</i> Infection. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004586.	3.0	25
124	The hookworm <i>Ancylostoma ceylanicum</i> intestinal transcriptome provides a platform for selecting drug and vaccine candidates. <i>Parasites and Vectors</i> , 2016, 9, 518.	2.5	19
125	Advancing a vaccine to prevent hookworm disease and anemia. <i>Vaccine</i> , 2016, 34, 3001-3005.	3.8	36
126	Advancing a vaccine to prevent human schistosomiasis. <i>Vaccine</i> , 2016, 34, 2988-2991.	3.8	90

#	ARTICLE	IF	CITATIONS
127	Human anthelmintic vaccines: Rationale and challenges. <i>Vaccine</i> , 2016, 34, 3549-3555.	3.8	49
128	Status of vaccine research and development of vaccines for Chagas disease. <i>Vaccine</i> , 2016, 34, 2996-3000.	3.8	56
129	Identification and Characterization of the <i>Trypanosoma cruzi</i> B-cell Superantigen Tc24. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 114-121.	1.4	11
130	<i>Trypanosoma cruzi</i> screening in Texas blood donors, 2008–2012. <i>Epidemiology and Infection</i> , 2016, 144, 1010-1013.	2.1	27
131	Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting. <i>Vaccine</i> , 2016, 34, 2197-2206.	3.8	33
132	Status of vaccine research and development of vaccines for leishmaniasis. <i>Vaccine</i> , 2016, 34, 2992-2995.	3.8	176
133	A therapeutic nanoparticle vaccine against <i>Trypanosoma cruzi</i> in a BALB/c mouse model of Chagas disease. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 976-987.	3.3	52
134	Expression and purification of an engineered, yeast-expressed <i>Leishmania donovani</i> nucleoside hydrolase with immunogenic properties. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1-14.	3.3	12
135	New Vaccines for the World's Poorest People. <i>Annual Review of Medicine</i> , 2016, 67, 405-417.	12.2	52
136	The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against <i>Onchocerca volvulus</i> in Mice. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004797.	3.0	20
137	The Global Economic and Health Burden of Human Hookworm Infection. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004922.	3.0	111
138	The human hookworm vaccine: recent updates and prospects for success. <i>Journal of Helminthology</i> , 2015, 89, 540-544.	1.0	26
139	Global Health and Tropical Medicine in the Twenty-First Century: A Renewed Interest in the Understanding and the Control of Helminth Infections. <i>Current Tropical Medicine Reports</i> , 2015, 2, 238-240.	3.7	0
140	Identification of immunodominant antigens for the laboratory diagnosis of toxocariasis. <i>Tropical Medicine and International Health</i> , 2015, 20, 1787-1796.	2.3	19
141	Expression, purification, and characterization of the <i>Necator americanus</i> aspartic protease-1 (APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1474-1488.	3.3	35
142	Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against <i>Trypanosoma cruzi</i> infection in mice. <i>Vaccine</i> , 2015, 33, 4505-4512.	3.8	41
143	Neglected Tropical Diseases among the Association of Southeast Asian Nations (ASEAN): Overview and Update. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003575.	3.0	97
144	The Gulf of Mexico: A "Hot Zone" for Neglected Tropical Diseases?. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003481.	3.0	5

#	ARTICLE	IF	CITATIONS
145	The Onchocerciasis Vaccine for Africaâ€™TOVAâ€™Initiative. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003422.	3.0	35
146	New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1251-1257.	3.3	15
147	Development of Chagas Cardiac Manifestations Among Texas Blood Donors. <i>American Journal of Cardiology</i> , 2015, 115, 113-117.	1.6	30
148	Vaccines against neglected tropical diseases: promising interventions to rescue the poorest populations in the Americas. <i>Immunotherapy</i> , 2014, 6, 117-119.	2.0	6
149	Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 648-658.	3.3	112
150	A Scoping Review and Prevalence Analysis of Soil-Transmitted Helminth Infections in Honduras. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2653.	3.0	20
151	Toxocariasis in North America: A Systematic Review. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3116.	3.0	88
152	Advancing a multivalent â€™Pan-anthelminticâ€™™ vaccine against soil-transmitted nematode infections. <i>Expert Review of Vaccines</i> , 2014, 13, 321-331.	4.4	65
153	Optimization and revision of the production process of the <i>Necator americanus</i> glutathione S-transferase 1 (<i>Nc</i> -GST-1), the lead hookworm vaccine recombinant protein candidate. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1914-1925.	3.3	35
154	Neglected tropical diseases in Central America and Panama: Review of their prevalence, populations at risk and impact on regional development. <i>International Journal for Parasitology</i> , 2014, 44, 597-603.	3.1	57
155	Current Tropical Medicine Reports: A Path Forward to Highlight Research and Clinical Advances, New Trends and Innovations. <i>Current Tropical Medicine Reports</i> , 2014, 1, 1-2.	3.7	0
156	Limited antigenic variation in the <i>Trypanosoma cruzi</i> candidate vaccine antigen TSA. <i>Parasite Immunology</i> , 2014, 36, 708-712.	1.5	7
157	Calling for rapid development of a safe and effective MERS vaccine. <i>Microbes and Infection</i> , 2014, 16, 529-531.	1.9	23
158	Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with <i>Onchocerca volvulus</i> in a mouse model. <i>International Journal for Parasitology</i> , 2014, 44, 637-646.	3.1	36
159	The Human Hookworm Vaccine. <i>Vaccine</i> , 2013, 31, B227-B232.	3.8	105
160	The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas. <i>Vaccine</i> , 2013, 31, 480-486.	3.8	51
161	Global economic burden of Chagas disease: a computational simulation model. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 342-348.	9.1	490
162	Innovation for the â€™Bottom 100 Millionâ€™™: Eliminating Neglected Tropical Diseases in the Americas. <i>Advances in Experimental Medicine and Biology</i> , 2013, 764, 1-12.	1.6	45

#	ARTICLE	IF	CITATIONS
163	New vaccines for neglected parasitic diseases and dengue. <i>Translational Research</i> , 2013, 162, 144-155.	5.0	126
164	A research capacity strengthening project for infectious diseases in Honduras: experience and lessons learned. <i>Global Health Action</i> , 2013, 6, 21643.	1.9	5
165	Ears of the Armadillo: Global Health Research and Neglected Diseases in Texas. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2021.	3.0	10
166	An Unfolding Tragedy of Chagas Disease in North America. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2300.	3.0	114
167	Expression at a 20L scale and purification of the extracellular domain of the <i>Schistosoma mansoni</i> TSP-2 recombinant protein. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2342-2350.	3.3	33
168	Biophysical and formulation studies of the <i>Schistosoma mansoni</i> TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2351-2361.	3.3	17
169	Chagas Disease: "The New HIV/AIDS of the Americas" <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1498.	3.0	184
170	Modeling the economic value of a Chagas™ disease therapeutic vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1293-1301.	3.3	62
171	Advances in vaccines against neglected tropical diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 765-776.	3.3	13
172	Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. <i>Expert Review of Vaccines</i> , 2012, 11, 1043-1055.	4.4	117
173	Expression, Immunogenicity, Histopathology, and Potency of a Mosquito-Based Malaria Transmission-Blocking Recombinant Vaccine. <i>Infection and Immunity</i> , 2012, 80, 1606-1614.	2.2	46
174	Expression, purification, and molecular analysis of the <i>Necator americanus</i> glutathione S-transferase 1 (Na-GST-1): A production process developed for a lead candidate recombinant hookworm vaccine antigen. <i>Protein Expression and Purification</i> , 2012, 83, 145-151.	1.3	31
175	Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. <i>Expert Review of Vaccines</i> , 2012, 11, 1405-1413.	4.4	126
176	Texas and Mexico: Sharing a Legacy of Poverty and Neglected Tropical Diseases. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1497.	3.0	47
177	Ac-AP-12, a novel factor Xa anticoagulant peptide from the esophageal glands of adult <i>Ancylostoma caninum</i> . <i>Molecular and Biochemical Parasitology</i> , 2011, 177, 42-48.	1.1	18
178	Expression, purification, crystallization and preliminary X-ray analysis of a truncated soluble domain of human glioma pathogenesis-related protein 1. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2010, 66, 1487-1489.	0.7	3
179	Molecular Cloning, Biochemical Characterization, and Partial Protective Immunity of the Heme-Binding Glutathione S-Transferases from the Human Hookworm <i>Necator americanus</i> . <i>Infection and Immunity</i> , 2010, 78, 1552-1563.	2.2	89
180	Potency testing for the experimental Na-GST-1 hookworm vaccine. <i>Expert Review of Vaccines</i> , 2010, 9, 1219-1230.	4.4	29

#	ARTICLE	IF	CITATIONS
181	An enzymatically inactivated hemoglobinase from <i>Necator americanus</i> induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection. <i>FASEB Journal</i> , 2009, 23, 3007-3019.	0.5	83
182	The Unfinished Public Health Agenda of Chagas Disease in the Era of Globalization. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e470.	3.0	28
183	Biophysical and Stabilization Studies of the <i>Chlamydia trachomatis</i> Mouse Pneumonitis Major Outer Membrane Protein. <i>Molecular Pharmaceutics</i> , 2009, 6, 1553-1561.	4.6	21
184	Model for product development of vaccines against neglected tropical diseases: a vaccine against human hookworm. <i>Expert Review of Vaccines</i> , 2008, 7, 1481-1492.	4.4	16
185	The Neglected Tropical Diseases of Latin America and the Caribbean: A Review of Disease Burden and Distribution and a Roadmap for Control and Elimination. <i>PLoS Neglected Tropical Diseases</i> , 2008, 2, e300.	3.0	562
186	Reduction of Worm Fecundity and Canine Host Blood Loss Mediates Protection against Hookworm Infection Elicited by Vaccination with Recombinant Ac-16. <i>Vaccine Journal</i> , 2007, 14, 281-287.	3.1	27
187	In vitro cultured peripheral blood mononuclear cells from patients with chronic schistosomiasis mansoni show immunomodulation of cyclin D1,2,3 in the presence of soluble egg antigens. <i>Microbes and Infection</i> , 2007, 9, 1493-1499.	1.9	7
188	Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells. <i>Oncogene</i> , 2007, 26, 5060-5069.	5.9	42
189	Vaccination with irradiated <i>Ancylostoma caninum</i> third stage larvae induces a Th2 protective response in dogs. <i>Vaccine</i> , 2006, 24, 501-509.	3.8	57
190	New technologies for the control of human hookworm infection. <i>Trends in Parasitology</i> , 2006, 22, 327-331.	3.3	84
191	The Impact of Concurrent and Treated <i>Ancylostoma ceylanicum</i> Hookworm Infections on the Immunogenicity of a Recombinant Hookworm Vaccine in Hamsters. <i>Journal of Infectious Diseases</i> , 2006, 193, 155-162.	4.0	27
192	<i>Ancylostoma caninum</i> MTP-1, an Astacin-Like Metalloprotease Secreted by Infective Hookworm Larvae, Is Involved in Tissue Migration. <i>Infection and Immunity</i> , 2006, 74, 961-967.	2.2	98
193	An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases. <i>Expert Review of Vaccines</i> , 2006, 5, 189-198.	4.4	21
194	The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation. <i>Oncogene</i> , 2005, 24, 525-540.	5.9	100
195	Vaccination with Recombinant Aspartic Hemoglobinase Reduces Parasite Load and Blood Loss after Hookworm Infection in Dogs. <i>PLoS Medicine</i> , 2005, 2, e295.	8.4	115
196	Antibodies against a secreted protein from hookworm larvae reduce the intensity of hookworm infection in humans and vaccinated laboratory animals. <i>FASEB Journal</i> , 2005, 19, 1743-1745.	0.5	169
197	Helminth Infections of Children: Prospects for Control. , 2005, 568, 135-144.		4
198	Immunogenicity of the Hookworm Na-ASP-2 Vaccine Candidate: Characterization of Humoral and Cellular Responses after Vaccination in the Sprague Dawley Rat. <i>Hum Vaccin</i> , 2005, 1, 123-128.	2.4	15

#	ARTICLE	IF	CITATIONS
199	Expression of the <i>Necator americanus</i> hookworm larval antigen Na-ASP-2 in <i>Pichia pastoris</i> and purification of the recombinant protein for use in human clinical trials. <i>Vaccine</i> , 2005, 23, 4754-4764.	3.8	88
200	Hookworm: "The Great Infection of Mankind". <i>PLoS Medicine</i> , 2005, 2, e67.	8.4	164
201	Mechanisms of HTLV-1 transformation. <i>Frontiers in Bioscience - Landmark</i> , 2004, 9, 2347.	3.0	17
202	Role of viral regulatory and accessory proteins in HIV-1 replication. <i>Frontiers in Bioscience - Landmark</i> , 2004, 9, 2388.	3.0	61
203	Protein Profile of Tax-associated Complexes. <i>Journal of Biological Chemistry</i> , 2004, 279, 495-508.	3.4	79
204	Vaccination of Dogs with a Recombinant Cysteine Protease from the Intestine of Canine Hookworms Diminishes the Fecundity and Growth of Worms. <i>Journal of Infectious Diseases</i> , 2004, 189, 1952-1961.	4.0	98
205	The role of cyclin D2 and p21/waf1 in human T-cell leukemia virus type 1 infected cells. <i>Retrovirology</i> , 2004, 1, 6.	2.0	49
206	Hookworm Infection. <i>New England Journal of Medicine</i> , 2004, 351, 799-807.	27.0	556
207	Progress in the development of a recombinant vaccine for human hookworm disease: The Human Hookworm Vaccine Initiative. <i>International Journal for Parasitology</i> , 2003, 33, 1245-1258.	3.1	137
208	Distinct Effects of Mitogens and the Actin Cytoskeleton on CREB and Pocket Protein Phosphorylation Control the Extent and Timing of Cyclin A Promoter Activity. <i>Molecular and Cellular Biology</i> , 2001, 21, 7607-7616.	2.3	28
209	$\alpha 5 \beta 1$ Integrin Controls Cyclin D1 Expression by Sustaining Mitogen-activated Protein Kinase Activity in Growth Factor-treated Cells. <i>Molecular Biology of the Cell</i> , 1999, 10, 3197-3204.	2.1	200
210	Regulation of P21 ^{cip1} Expression by Growth Factors and the Extracellular Matrix Reveals a Role for Transient ERK Activity in G1 Phase. <i>Journal of Cell Biology</i> , 1999, 146, 1255-1264.	5.2	126
211	Role of the Extracellular Matrix and Cytoskeleton in the Regulation of Cyclins, Cyclin-dependent Kinase Inhibitors, and Anchorage-Dependent Growth. <i>Advances in Molecular and Cell Biology</i> , 1997, 24, 57-75.	0.1	1
212	Expression of the <i>c-ski</i> Proto-Oncogene During Cell Cycle Arrest and Myogenic Differentiation. <i>DNA and Cell Biology</i> , 1995, 14, 701-707.	1.9	11